6634 ªYÄ£
ªÑ¥»: 3.832»õ
¥Dn·~°È:
¨xŦ¯e¯fªvÀø¤Î¯kµhªvÀø¬ÛÃöÃĪ«¬ã¨s¤Î¶}µo
¸³ºÊ«ùªÑ¤ñ¨Ò: 21.7%(¼W¥[¤¤)
¥~¸ê«ùªÑ¤ñ¨Ò: 0.22%(¼W¥[¤¤)
Ä~Äò©¹¤U¬Ý...!
=============================================================================
²£«~01¡GSNP-610 (ªvÀø¯×ªÕ¨x¯e¯f·sÃÄ)
¾AÀ³¯g: «D°sºë©Ê¯×ªÕ¨xª¢
²£«~Àu¶Õ:
1.¥Ø«e©|µL¼Ð·ÇªvÀøÃĪ«
2.¥«³õº¨£·sÃÄ(First-in-class)
3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x
4.µL¦w¥þ©Ê°ÝÃD
¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C
Ävª§¤O:
1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢
2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯×
3.¥i´£¥X¨uÃĥӽСAÀ³¥Î©óªvÀø§³®W«æ©Ê¯×ªÕ¨x
¬ãµo¶¥¬q:
1.¤w³q¹LUSFDA¤ÎTFDA¼f¬d¶i¤JÁ{§É¤G´Á
2.Á{§ÉÀø®Ä¤Î·sªvÀø¾÷ÂàÅçÃÒ
Àø®Ä¤ÀªR¡G
1.²Ä¤@´ÁÁ{§É¸ÕÅç¡Gµ²ªGÅã¥Ü¤HÅé¨Ï¥Î¦w¥þ¡A©Ê½è¨}¦n
2.²Ä¤G´ÁÁ{§É¸ÕÅç¨ä¤¤¤ÀªR¡G17¦ìNASH ¯f¤H (p=0.009)
=============================================================================
²£«~02¡GSNP-630
¾AÀ³¯g:«D°sºë©Ê¯×ªÕ¨xª¢
²£«~Àu¶Õ:
1.¬°Àu¤Æ(Optimized)¤§·s¤Æ¾Ç¹êÅé(NCE)
2.¥«³õº¨£·sÃÄ(First-in-class)
3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x
4.§@¬°²Ä¤@¥N²£«~¤W¥««áªº±µÄò¦û¦³¥«³õ¤§²£«~
¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C
Ävª§¤O:
1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢
2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯×
3.Àu¤ÆªºÀø®Ä±j«×¡B§@¥Î®É¶¡
4.µL¦w¥þ©Ê°ÝÃD
¬ãµo¶¥¬q:
1.Á{§É«e
2.¹w©w¥Ó½Ð¬ü°êFDAIND¡B§Ö³t³q¹D(fasttrack)¡C
3.¥Ó½Ð¬ü°ê¬ð¯}©ÊªvÀø(breakthrough therapy)ªº»{©w¡C
Àø®Ä¤ÀªR¡G
1. ¥Ø«e¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.05
=============================================================================
²£«~03¡GSNP-810 (µL¨x¬r©Ê¤îµh·sÃÄ¡B¸Ñ¬r¾¯)
¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃÄ (¸Ñ¼öÂíµh¾¯)
²£«~Àu¶Õ:
1.¦w¥þ¤Æ¦Xª«·s²Õ¦X¡BµL¨x¬r©Ê
2.¸Ñ¨M¢¤ÁÂåÀø»Ý¨D (Important urgent unmet medical needs)
3.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥iקï©Î§R°£FDA¨x¬rĵ»y¥i¼W¥[¾¯¶q
¥«³õ: ¤AñQÓi×ô¶È¦b¬ü°ê¤@¦~´N¦³40»õ¬ü¤¸ªº¥«³õ
Ävª§¤O:
1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«
2.¥i§ð¦û¼s¤j¥«³õ¡]NSAID, COX-2 §í¨î¾¯¡BOpioidsÃþ¤îµhÃÄ¥«³õ¡^
3.¥i¬Ù°£¶D³^¶O¡B±Ð¨|°V½m¶O
¬ãµo¶¥¬q:
1.¤w§¹¦¨§C¾¯¶q¡B°ª¾¯¶qÁ{§É¸ÕÅç
2.¤w¥Ó½ÐUSFDA¼Ï纽Á{§É¸ÕÅç¡B±N¥Ó½Ð¬ð¯}©Ê¼f¬d/§Ö³t³q¹D
3.µL¨x¬r©Ê¤AñQÓi×ô¸Ñ¬r¾¯¦¨¤À¡A¤w¥Ó½Ð¬dÅçµn°O¥Î¤§Á{§É¸ÕÅç
=============================================================================
²£«~04¡GSNP-830/ SNP-840
¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃĽƤè(ªvÀø¤¤¡B««×¯kµh)
²£«~Àu¶Õ:
1.µL¨x¬r©Ê¤AñQÓi×ôªº½Æ¤è
2.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥iקï©Î§R°£FDA¨x¬rĵ»y¡A¥i¼W¥[¾¯¶q
¥«³õ: ¤AñQÓi×ô³B¤èÃĦb¬ü°ê¤@¦~´N¦³27»õ¬ü¤¸ªº¥«³õ
Ävª§¤O:
1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«½Æ¤è
2.½Æ¤è¤w¥Ñ¬ü°êFDAn¨D°¾¯¶q§C©ó325²@§J¡A±N¼vÅTÀø®Ä
3.¦³¨Ï¥Î±M§Q¡A¥iקï©Î§R°£FDA¨x¬rĵ»y
4.¥i¼W¥[¤AñQÓi×ô¾¯¶q
¡]¥Ñ325mg ¦^´_¦Ü500 mg¬Æ¦Ü§ó°ª¡A·|¸û¦³®Ä¡^¥H¼W¥[Àø®Ä¡A©Î´î¤ÖOpioids¾¯¶q¡A°§C¦¨Å}°Æ§@¥Î
5.¤GªÌ¾Ü¤@±ÂÅv
6.¥i¼W¥[¥«¦û²v
¬ãµo¶¥¬q:
1.SNP-810¨ú±oÃÄÃÒ«á¡A¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê¸ÕÅç
SNP-830 ¤£¬O ·s¦¨¤À ªº·sÃÄ¡A©Ò¥H¤£»Ýn¶i¦æ²Ä¤@¡A¤G¤Î¤T´ÁÁ{§É´úÅç
µ¥ SNP-810 ®³¨ìÃÄÃÒ«á¡A¥H ·sÀø®Ä½Æ¤è¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê´úÅç ´N¥i¥HÀò±oÃÄÃÒ
=============================================================================
*****************************************************************************
SNP-8 ¨t¦C Àø®Ä¤ÀªR¡G
1. ¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005
1. ¤w¸g§¹¦¨¤§¤HÅé¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005
=============================================================================
*****************************************************************************
¥¼¨Ó¥Ø¼Ð±ÂÅv¥D¤O²£«~¡G
1. ¯×ªÕ¨xÃÄ¡GSNP-610 ©M SNP-630 ¦U¦³ÀuÂI¡A¥Ø¼Ð¬°¥þ²y±ÂÅv
2. ¤îµhÃÄ(OTC): SNP-810, ¥Ø¼Ð¬°¬ü°ê¤Î¥þ²y±ÂÅv
3. ¤îµhÃÄ(³B¤èÃÄ): SNP-830 ¤Î SNP-840, ¦b°Êª«¤W¬Ò¦³¥¿±ªºµ²ªG¡A¥Ø¼Ð¬°¥þ²y±ÂÅv
=============================================================================
*****************************************************************************
¥Ø«e¤½¥q»P°ê»Ú¤j«¬Ãļt¥¿¦b½Í§Þ³N±ÂÅv©M¦X§@p¹º
§Ú¬Ý¹L¤½¥q©xºô©M©Ò´£¨Ñªº¸ê®Æ¡Aı±o¤½¥q«Ü¥Î¤ß¦b¸gÀç¡A¦Ó¥B¸ê®Æ¤]«Ü¸Ô²Ó
¹ï¤½¥qµo®i«Ü¦³¦Û«H¡A¥¼¨ÓªÑ»ùȱo´Á«Ý¡A¦³¾÷·|¬O ¤U¤@Ó ¦X¤@ ÄƪÑ
-----------------------------------------------------------------------------
¥H¤W¸ê®Æ ³£°Ñ¦Ò ªÑªF·|ij¨Æ¿ý.pdf ©M ¤½¥q©xºô (¦³¿³½ìµÛÅwªï¦A²`¤J¬ã¨s»P°Q½×)
CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21
SNP-610Àø®Ä¦w¥þÀu©óElafibranor (PPAR£\/£_¿E动剂)
---------------------------------------------------------------------------------------------------
www.x-mol.com/paper/1492209434695598080?adv
¥Ø«eªº结ªG«Ø¥ß¤F PPAR £\©M CYP2E1¤§间ªº¥N谢¦êÊð¡A
[³q过¹v¦V CYP2E1 来调节内·½©Ê¥N谢ª«¡A¶W¥X¨ä¦b¥~·½©Ê¥N谢¤¤ªº¨å«¬§@¥Î] <--->¤j¥Õ¸Ü¬O[SNP-610§í¨îCYP2E1¡A¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[¦Ó¿E¬¡PPAR£\¡A¶W¥XElafibranor ³oºØ¥~·½©ÊÃĪ«ªº¿E¬¡PPAR£\§@¥Î]
SNP-610Àø®Ä¦w¥þÀu©óElafibranor (PPAR£\/£_¿E动剂)
¦³¨S¦³Àu©óAkeroªºEfruxifermin ? (Akero¦b2019¦~5¤ë©Û¦¬²Ä1¦ìP2±wªÌ¡AP2¼Æ¾Ú¬O¥h¦~¤½¥¬¡AµM«áªYÄ£¤½¥¬ªº¼Æ¾Ú«Ü¤Ö¡AµLªk¿s¤@´³¦Óª¾¥þ°\¡A©Ò¥H¨S±o¤ñ)
---------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151µoªí®É¶¡¡G2020/7/3¤W¤È08:05:38²Ä35½g¦^Î`
108/07/24 Bio-Asia¨È¬w¥Í§Þ¤j®iÁ|¿ì¤§¤½¥q®i±æ»¡©ú·| mops.twse.com.tw/nas/STR/663420190724M001.pdf
Phase II study:
- The decreases in several clinical parameters from
baseline to the end of treatment were greater in
SNP-610-12-week treatment than Ocaliva,Cenicriviroc, Elafibranor, MGL3196 or Selonsertib
--------------------------------------------------------------------------------------------
±q[½è]¨Ó¬Ý: SNP-610/SNP-630§í¨îCYP2E1À³¸Ó¬O¸ûÀu(²×¨s¬Oì¥Äì¨ý¥Ñ¨xŦ¤ÀªcªºFGF21)¡C
±q[¶q]¨Ó¬Ý: AkeroªºEfruxifermin¯à¥[¤JFGF21Ãþ¦üª«¨ì·¸¥X¡C
±EÀu???
¥\¤Ò¦Ê¦ÊºØ
¦³®Äªº¤~¬O¯u¥\¤Ò
¥Ø«eªºM¤ÎA¤½¥q¸ÕÅ禳®Ä
¾÷Âà¤j·§¬Û¦P
ªYÄ£ªº¾÷Âà¤]¸ò¥L̬ۦP
¡u¦³¨S¦³®Ä¡v¸ÕÅç¼Æ¾Ú»¡¸Ü
Gene expression biomarkers [ Time Frame: 12 weeks ]
Gene expression biomarkers (ACC1, Adfp, AOX, Cat, CCL20, CCR2, Cpt1£\, CYP2E1, CYP4A11, CYP7A, Dgat1, Dgat2, FAS, Gapdh, Gpx1, Gpx2, Gpx3, Gpx4, GSS, Hadh, Ho1, HSL, IL-10, IL-1£], IL-6, iNOS, LCAD, NF-£eB1, NF-£eB2, Ppar£\, PPAR£]/£_, PPAR£^, SCD-1, Sod1, Sod2, Sod3, SREBP-1c, TGF£], TLR4, TNF£\, Ucp2, VLCAD, £\-SMA, £]-actin) related to NASH changes in blood at Week 12
-----------------------------------------------------------------------------------------------
SNP-610ªºP2 ¡A ¼Ð»xª«¯u¬OµY²wº¡¥Ø¡A´N¬O¨S¦³ÀË´úFGF21.
¥¿±:
1.Saroglitazar(PPAR-£\/£^ Âù«¿E°Ê¾¯)¬O¥Ø«e¥@¬É°ß¤@¤äNASHÃĪ«¡A¥u¦b¦L«×§åã¤W¥«(¬ü°êÁ{§É¤¤¡AFDAÁÙ¨S§åã)
2.AkeroªºEfruxifermin(FGF21Ãþ¦üª«)¬O¥Ø«eP2¼Æ¾Ú³Ì¨Î
3.MadrigalªºResmetirom(THR-£]¿E°Ê¾¯)-->¤]·|¿E¬¡FGF21
t±:¿E¬¡PPAR£\»P¿E¬¡FGF21ªºÃĪ«¡A³£¦³Á{§É¥¢±ÑªÌ!
TRPV4 ¿E¬¡¤º¥Ö¤@®ñ¤Æ´á¦X酶³q¹L [ªýÂ_CYP2E1]¤¶¾Éªº®ñ¤ÆÁÙì¬r©Ê¨Ó©è§Ü«D°sºë©Ê¯×ªÕ¨x
www.ncbi.nlm.nih.gov/pmc/articles/PMC5989309/
¥D¤£¥D¬y¨Ã¤£¬O«ÂI
ÃĦ³¨S¦³®Ä¤~¬O«ÂI
±zª¾¤£ª¾¹DGALTªº¸ÕÅç¼Æ¾Ú¦p¦ó¡H
¸Ó½×¤å¦³¸g¦P¦æ¼f¬dµoªí(Impact Factor:11.614)
2022.11.28 link.springer.com/article/10.1007/s12272-022-01419-w
CYP2E1 ¤ô¥¥i¯à¦b FGF21 ªí¹F¤¤«Ü«n¡FCYP2E1 ªº¯Ê¥F¬O¿E¬¡ PPAR£\-FGF21 ¶b©Ò¥²»Ýªº¡A¨Ã¥B¥i¦³®Ä´î¤ÖªÎD
--------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/28 ¤U¤È 05:22:04²Ä 2031 ½g¦^À³
ªYÄ£¥²nÅçÃÒ³o½g½×¤å´£¥Xªº¾÷¨î:SNP610(CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21)¡C
2022.5¤ë www.sciencedirect.com/science/article/pii/S2211383522000545
¥Ñ©ó CYP2E1 ¥Dn¦b¥Dnµo¥Í¥NÁªº¨x²ÓM¤¤ªí¹F¡A¹v¦V§í¨î CYP2E1 ¥i¯à¹ê²{ì¦ì¨x²ÓM¤¤ªº PPAR £\¿E¬¡¡A³o¥i¥HÁ×
§KÁ{§É¤¤°¸º¸µo¥Íªº«D²Õ´¯S²§©Ê PPAR £\¿E¬¡ªº°Æ§@¥Î--->SNP-610Àø®Ä¦w¥þÀu©óElafibranor (PPAR£\/£_¿E动剂)
¦ôȸòMOAÁÙ¬O«Ü¦³Ãö«Yªº¡A89ªºMOA FGF21 ¬O«D±`¥D¬yªº¡AªYÄ£µLªk¤ñ¡C
¤]¤£¬O©Ò¦³¤½¥q¦b¬ü°ê±¾µP´N¦³°ªªÑ»ù¡A°Ñ¦ÒGALT ¥L°µ¨ì2/3´Á¤F¡C
±q¥h¦~©³¡A¨º´µ¹F§J¤W¥«ªºNASH ±Ú¸s¤jº¦´X¿¨Ó¬Ý¡C
¤£ºÞ¬O³Ì»â¥ýªºM¤½¥qªÑ»ù´¿¶W¹L300¬ü¤¸
§Y¨Ï1b/2aªº89³£§Ö14¬ü¤¸
¤½¥qÁnºÙ¬Y¨Ç¼Æ¾ÚÀu©óM¤½¥q
¥Ø«eªÑ»ù¤U¶^¨ì3¬ü¤¸¥ª¥k¡A¥u¦³M¤½¥qªº¹sÀY¡C
¥ý³£¤£¥h¦C¤J810¼Ï¶s¸ÕÅç¡B±ÂÅv¨Æ©y¡C
¥ú¤ñ¸û89¤½¥q´N¦n¡AªYÄ£¥Ø«eªº»ù®æ©e©}¨ì¤£¦æ¡C
¥HªYÄ£6¤Î8¨t¦C¥Ø«e©Ò¤½¥¬ªº¸ÕÅç¼Æ¾ÚÅã¥Ü¤Î¨â¶µ·sÃÄ¥«³õ³W¼Ò
Y¦b¨º´µ¹F§J¤W¥«¡AªÑ»ù¦A«ç»ò®t¤]¤ñ89¦n¡C
©Ò¥H±j¯P«Øij-ªYÄ£¨ì¨º´µ¹F§J¤W¥«¡C
¤]½Ð¤j®a¦h¦h¤ä«ù¡A«Øij¤½¥q¨ì¨º«ü¤W¥«¡C
¦³³\¦h¤£@¤[µ¥ªºµu½uÄw½X¡Aµ¥¤£¨ì±ÂÅv¥X¨Ó¡C
¦A¥[¤WÂà¤WÂd§Y¦³¥i¯à·|©µ«á¡A´N·|ÄÀ¥XÄw½X¡AªÑ»ù¦ÛµM·|¤UסI
¤Uפ£¨£±o¬OÃa¨Æ¡A¸Ó¦³ªº»ùȮɡAªø½u§ë¸ê¤H¦ÛµM´N·|¶R¨«¡C
«H¤£«H¡H
ªYÄ£¦pªG«Å¥¬±N¨ì¨º´µ¹F§J¤W¥«¡AªÑ»ù´N¨göt¡H
1.¤j§Q¦h¤£º¦¥²¦³ÁôÂçQªÅ,³o¬OªÑ¥«ÅK«ß:a.ªñ¤ë¤j½L¤Î¥Í§Þ¤jº¦,6634¤Ï¶^; b.810¤w¸g¹F¼Ï¯Ã¶¥¬q,±ÂÅv¤]¥Ñ2020´N¶}©l½Í.
2.¤½¥q¥DºÞ¦b½æªÑ²¼. ¤º³¡¥DºÞ³Ì¤F¸Ñ¤½¥qÀç¹B.
ªÑ»ù¬O©Ò¦³¥«³õ²³¤H¹ï¤½¥q¬Ýªk.©Ò¦³§ë¸ê¤H³£¥²¶·´L«¥«³õ. ¨ä¦¸§Ú¦A¦¸±j½Õ°ê»Ú°Ó°È½Í§P¬O«D±`±M·~§Þ¯à,¨Ã¤£¾A¦X¥Ñ¨S¦³°ê»Ú½Í§P¸gÅç§Þ³N¤Hû¥D½Í. ªÑ¥«·s³Ð¤½¥q¤×¨ä¬O¥Í§Þ¤½¥q, ¦b²£«~2-3´ÁÁ{§É¸êª÷¥R¨¬«á©¹©¹Â§¸u²£·~°ê»Ú¤H¤~¥D«ù°ê»Ú¤Æ½Í§P±ÂÅv.
¦A±j½Õ¤@¦¸. ¤j®a³£¬O6634§ë¸ê«ùªÑªÌ.§Ṳ́@°_·þ«P¤½¥q¥úÄ£,¤j®a¤@°_ÁÈ¿ú.¤]¤@°_µ¹¤½¥q«Ø¨¥Åý¤½¥q§ó¦n.§Ú¤]ÁÙ¬Oºû«ù·í®É¶R¶i®É¬Ýªk: ±ÂÅv¥i¯àn1¦~«á, §Ú·|«ùªÑ2¦~.
§Ú»¡n§ë¸ê«ù¦³2¦~, ²{¦b«ù¦³¤¤.
»¡n§ë¸ê¤¦~¥H¤Wµ²ªG¦Ñ¬OÃöª`µu´ÁªÑ»ùµo®i¡AÁ`¬O®³ªñ´Áªí¥ýÀu²§ªºªÑ²¼¨Ó¤ñ¸û¡A§ë¸êÁÙ¬O§ë¾÷?
ªÑ»ù¨Sªí²{´N»¡¸gÀç¼h¦³°ÝÃDn¦V¨ä¥L¤½¥q¾Ç²ß¡A«¢«¢«¢«¢«¢
810 ¤w¨ì¼Ï¯Ã¶¥¬q, §¹¥þ¥i¥H±ÂÅv¤F. À³¸Ó¬O°ê»Ú½Í§P¤H¤~¯Ê¥F. 6885 ³Ìªñ´N¸u¶±°ê»Ú½Í§P¤H¤~±M³d±ÂÅv¨Æ©y.
¬°ÓV¸Ñ¯Ê³f±¡¶Õ¡AFDA¦b1¤ë»P2¤ëµo¥¬§ó·s¥¬¬¥ªâ¤fªA²VÄa²G[½Æ¤è]ªºÂ²¤Æ«ü«n¡A¦Ó¤AñQÓi×ô½Æ¤è¦][¨x¬r©Ê]¡A¤£¯Ç¤J!
1. 2023.1.23
www.fda.gov/drugs/human-drug-compounding/questions-and-answers-compounded-oral-suspension-medications-pain-and-fever
2.2023.2.23 -ijû©IÆ~ FDA ¸Ñ¨M¥¬¬¥ªâ©M¹ï¤A酰®ò°ò×ôµu¯Ê°ÝÃD khanna.house.gov/media/press-releases/release-ro-khanna-calls-fda-tackle-ibuprofen-and-acetaminophen-shortages
3.2023.1.30 ®õ¿Õµu¯Ê:¬°¤°»ò¥¦¨Ñ¤£À³¨D parade.com/health/tylenol-shortage
´X¦~«eJ&J¦bª÷¤s«Ø¥ß¤F¶Ç¬V¯f¬ãµo¤¤¤ß¡AµM«á¥h¦~§â¥þ²y¬ãµoR&D¤j³¡¤À³£·h¨ì¤Fª÷¤s¡C¦ý¤µ¦~¶}¦~J&J§â¾ãÓèè«Ø¥ß¨S¦h¤[ªº¶Ç¬V¯f³¡ªù´X¥G¥þµô¤F¡C
2023.2.21--¦Ê»õ³W¼ÒªºNASH¥«³õ¡A¯à§_«P¦¨MNCªº²Ä¤G¼Wªø¦±½u¡H zhuanlan.zhihu.com/p/608286704
01 ¶r¯à¤O¡G¶R¨ÓªºNASH¬G¨Æ ¥¤ß¦Ó½×¡A±j¥Í¤§©óNASHµLºÃ¬O·s¤â¡C
...¬°¤F¹ê²{Ås¹D¶W¨®¡A±j¥Í³Ìªì¿ï¾Ü¤@ºØ1«¬¤j³Â¯À¡]CB1¡^¨üÅéÃĪ«Namacizumab¡]RYI-018¡^...
02 RNAiÀøªk¡A¨ì©³¦æ¤£¦æ¡H
...¨º»ò¡A°ÝÃD¤S¶¤F¦^¨Ó¡C¬JµM²£«~¨ã³Æ¼ç¤O©M®t²§¤Æ¡A±j¥Í¬°¦ó¿ï¾Ü¦b¦¹¨è°h¥X¡H
03 §Ú¡AMNC¡A2023¨DÓ¦wÃ
...°²¦pAD¬O°h¦æ©Ê¯«¸g¯e¯f»â°ìªº¡§¬ãµo¶Â¬}¡¨¡ANASH«h¬O¥NÁ¯e¯fªº¡§¼X³õ¡¨¡C
...·íµM¡ANASH³o¶ô³J¿|¤£¬O¤£¦Y¡A¤£±Æ°£±j¥Í¦b®É¾÷¦¨¼ô«á¥b¸ô±þ¦^¡AÂǵۻP¦X§@Biotechªº«á´Á¦¨¼ô¸ê²£¸ó¤JÂÅ®ü¡C
1. 2023.2.14--NASH©ö·P©Êªº¿ò¶Ç®t²§(¸ê§UªÌ:Janssen Pharmaceuticals¼b¥Í¶°¹Î)
...§ÚÌ´ú¸Õ¤F¤CºØ¤p¹««~«Y¹ï NASH ªº©ö·P©Ê...[ªí©ú½u²ÉÅé¥\¯à»Ùê¦b NASH ¶i®i¤¤°_µÛ®Ö¤ß§@¥Î¡C]
[ªí©ú½u²ÉÅé¥\¯à»Ùê¦b NASH ¶i®i¤¤°_µÛ®Ö¤ß§@¥Î¡C]«nªº¡APWK/PhJ ¤p¹«ªº NASH °ò¦]ªí¹FÃлP¤HÃþNASH ¯S¼xªº«
Å|«×³Ì°ª¡C
---------------------------------------------------------------------------------------------------
actu.epfl.ch/news/modeling-liver-and-kidney-disease/
EPFLªºAuwerx¹Î¶¤»PJanssen Pharmaceuticals ªº¬ì¾Ç®a¤@°_¶}®i¤F¤@¶µ¬ã¨s¡A¥H«Ø¥ß¤CºØ¤p¹«µÇ·l¶Ë¼Ò«¬ªº¤ÏÀ³
...PWK/PhJ «~¨tªº¤p¹«¹ï NAFLD/NASH ³Ì±Ó·P¡A¤]¬O°ß¤@Åã¥Ü¥X¶i®i¬°ÅÖºû¤Æ NASH ªº«~¨t¡C
-------------------------------------------------------------------------------------
¶R®a±N½æ®aªºÃĪ«¾É¤J¤WzªºNASH°Êª«¼Ò«¬¡A¨ÓÓ[ÀY¹ïÀY]°Êª«¹êÅç¡AÅý¥¦Ìª½±µPK¡A±EÀu¶R½Ö!
¦¶³Í¥Á±µ¨ü¤¤¥¡ªÀ°OªÌ±M³X®Éªí¥Ü¡A¦b¬ü°ê¦³600¦hºØ¡B¥xÆW¦³ªñ300ºØ·P«_ÃÄ¡B¤îµhÃÄ¡A§t¦³Acetaminophen¡]¤AñQÓi×ô¡^¦¨¤À¡A¬O¥þ²y¨Ï¥Î³Ì¼sªº¸Ñ¼öÂíµh¾¯¡A¦ý¤]¬O¥þ¥@¬É³y¦¨ÃĪ«¨x¬r©Ê²Ä1¦WªºÃĪ«¡CªYÄ£¹Î¶¤¸Ñ¶}¤F³oÓªø¹F40¦~ªºÃøÃD¡C
¬ü°ê¹«~º[ÃĪ«ºÞ²z§½¡]FDA¡^ªñ40¦~¨Ó«ùÄòn¨D¬ÛÃöÃļt¿n·¥¸Ñ¨M¨x¬r©Ê°Æ§@¥Îªº°ÝÃD¡A¨´¤µ©|¥¼§¹¥þ¸Ñ¨M¡C¤AñQÓi×ô¬O¾ÉP¥þ²yÃĪ««æ©Ê¨x°IºÜªº¥Dnì¦]¤§¤@¡A¥e^°ê«æ©Ê¨x°IºÜ±wªÌ¬ù57%¡]1200¤H¡^¡A¥e¬ü°ê«æ©Ê¨x°IºÜ±wªÌ¬ù39%¡]2000¤H¡^¡C
¦¶³Í¥Áªí¥Ü¡AµL¨x¬r©Ê¤îµhÃÄSNP-810¡]¦w®õ®³¯k¡^©ó2020¦~¡B2021¦~¤À§O»P2®a°ê»Ú¯ÅÃļtñq¦X§@¨óij¡AµL©`´Á¶¡¨ä¤¤¤@®a¦X§@¼t°Ó½T»{¸ÕÅçµ²ªG¤£¦p¹w´Á¡A¥HP¦X§@¤¤¤î¡C
¤£¹L¡AªYÄ£¹Î¶¤¨S¦³©ñ±ó¡A§ä¥X°ÝÃD¡Bקï¬ã¨spµe¤¤ªº¤@¶µ±ø¥ó«á¡A¦b¦P¤@®a¸ÕÅ礽¥q«±Ò¸ÕÅç¡A9¤ë22¤éÀò±o¥¿¦¡¸ÕÅç³ø§i¡AÃÒ¹êSNP-810¬°µL¨x¬r©Ê¡C¤é«e¤w´£¨Ñ°Êª«¸ÕÅçµ²ªGµ¹»P¤½¥qñq¦³Àv¦X¬ùªº°ê»Ú¤îµhÃļt°Ó¡C
ªYÄ£¬ãµoªº¤îµhÃÄ«·s½T»{ÃҹꬰµL¨x¬r©Ê¡A¤]Åýº®a°ê»Ú¤j¼t¦X§@®×¦³¾÷·|¡u±Ñ³¡´_¬¡¡v¡C
¾¨ºÞ«±Ò¦X§@±ÂÅv®×¬¢½Íªº¶i«×µLªk³zÅS¡A¤£¹L¦¶³Í¥Á»{¬°¡AªYÄ£¸Ñ¶}¤F¤î¯kÃÄ40¦h¦~¨Ó©l²×¸Ñ¤£¤Fªº¶Ë¨xÃøÃD¡A¥¼¨Ó¦³¼Æ¦ÊºØ§t¦³¦¹¦¨¤ÀÃĪ«»Ý³Q´À¥N¡F¬Û«H«Ü§Ö´N¯à¦b°ê»Ú»R¥x¤Wµo¥ú¡A¹ê²{¥ø·~¤T¤jÄ@´º¤¤ªº²Ä¤@¶µ¥Ø¼Ð¡u¶}µo·sÃÄ¡Aµn¤W°ê»Ú»R¥x¡v¡AÁÚ¦VÀò§Q¤§¸ô¤w¶V¨Ó¶V±µªñ¡C
¦¶³Í¥Áªí¥Ü¡A¥Ñ©ó¦³®ÄÃIJzªº¥D¦¨¤À¨S¦³§ïÅÜ¡AY¦¨¥\±NSNP-810±ÂÅvµ¹¥Ø«e¾P°â¤AñQÓi×ô¦¨¤À¤îµhÃĪº¤j¼t¡A¤£¥Î«·s°µÁ{§É¥Ó½ÐÃÄÃÒ¡A¥u»Ýn§ó§ï¥]¸Ë¤Î¥é³æ¡A´N¯à¥H³Ì§Öªº³t«×¾P°â¶i¶¥ª©¡]¤£¶Ë¨x¡^²£«~¡C
¦Ü©ó±ÂÅv¼Ò¦¡¡A¦¶³Í¥Á»¡¡A¥@¬É¯Å¤jÃļt³£¬O¥H¡u¤½¦@½Ã¥Íªº»ùÈ¡v¬°³Ì¤j©v¦®¡A¦]¦¹¥¼¨Ó±N±Ä«D±MÄÝ¡B¤À°Ï±ÂÅvµ¦²¤¡A²{¶¥¬q±ÂÅvºN¦¡¤£³]±Ä¨ú¶}©ñºA«×¡ASNP-810¤]¤w¨ú±o¬ü°êOTC¡]«D³B¤èÃÄ¡^¥«³õ¾P°âÅv¡C
¡u¿ïÃD¡B¤H¤~¡B´¼¼z°]²£«OÅ@¦n¤£¦n¡B°]°È±Ã©w«×¡A³£¬O·sÃĤ½¥q¦¨¥\ªº¥ý¨M±ø¥ó¡v¡C¦¶³Í¥Á«ü¥X¡AªYÄ£±Mª`¥H¤HÅé¥NÁȕÀ¬¡©Ê½Õ±±µ¥¬ÛÃö±M§Q§Þ³N¡A¶}µo¤îµh¤Î¨xŦ¯e¯f·sÃÄ¡AP¤O¸Ñ¨M¥Ø«eÁ{§ÉªvÀø¤W©Ò¾D¹J¦Ó©|«E«Ý¸Ñ¨MªºÃøÃD¡C
¦¶³Í¥Áªí¥Ü¡A¦bµL¨x¬r©Ê¤îµhÃÄSNP-810ÁÚ¤J·sªº¨½µ{¸O«á¡A¤]±N¶i¦æ¤îµh¥[³Â¾K¾¯ªº½Æ¤è¤fªAÃÄ«~¬ãµo¡A¥Î¥H¦]À³¤¤«¯f¯kµh¡A¸Ñ¨M¥Ø«eÃþ¾~¤ù¤îµhÃĪ«¶Ü°Øµ¥¦¨Å}°ÝÃD¡F¦P®É±N¥[³t¯×ªÕ¨x·sÃÄSNP-610¶}µo¡Aº¥ý±NÂX¼W1¿ªº¬ãµo¤Hû¡C
®Ú¾Ú¼w·N§Ó»È¦æ¤ÎÂåÃÄ¥«½Õ¤½¥qEvaluate Pharmaªº¹w´ú¡A¥þ²y«D°sºë©Ê¯×ªÕ¨xª¢¡]NASH¡^ÃĪ«ªº¥«³õ³W¼Ò¦b2025¦~¤W¬Ý350»õ¦Ü400»õ¬ü¤¸¡C¦¶³Í¥Á»{¬°¡A¥Ø«eNASH©|µL¼Ð·ÇªvÀøÃĪ«¡A¼ç¦b°Ó¾÷Ãe¤j¡A¥i¦P®É®e¯Ç¦hÓ·sÃÄ¡C¥L«ü¥X¡AªYÄ£¥¿¿n·¥´M¨D»P°ê¥~¤j¼t¦@¦P¦X§@©Î±ÂÅvµ¥¨Æ©y¡C
Richard C. Dart, MD, PhD:
1.McNeil Consumer HealthcareÅU°Ý
2. RMPDS ¥D¥ô www.rmpds.org/about-rmpds/leadership-team.html
60 ¦h¦~¨Ó¡ARMPDS ¤@ª½¬°¤½¦@©M¨pÀ糡ªù´£¨Ñ±M®aÂåÀø«Øij¡C¦b¨º¬q®É¶¡¸Ì¡A§Ṳ́w¸g¦¨¬°¬ü°ê³Ì¤jªº¬rª«¤¤¤ß¤§¤@¡A¨Ã¥B¬O¬r©Ê¡B¶Ë®`©M¯e¯f¬ã¨sªº»â¾ÉªÌ¡C§Ú̬°¥@¬É¤W¤@¨Ç³Ì¤jªº»sÃĤ½¥q´£¨ÑÂåÀø«H®§©M¼i¦æ¡BÃĪ«¦w¥þ³ø§i©MÀݥκʴúªA°È¡C§ÚÌÁÙ¦b¸Ñ¬r¾¯¶}µo¤è±¶}ÅP¤F¹D¸ô¡A¨Ã¬°©t¨àÃĤ½¥q©M¤j«¬»sÃĤ½¥qºÞ²z¤F³\¦h¦h¤¤¤ßÁ{§É¸ÕÅ綵¥Ø¡C
-------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/23 ¤W¤È 07:26:33²Ä 2950 ½g¦^À³
SNP-810 Á{§É¼Æ¾Ú´îNAPQI§Î¦¨:Dr. Richard C. Dartªí¥Ü¡A
[¤AñQÓi×ô¦b«ØijªvÀø¾¯¶q(4g)¤U¡A¤]´¿¦³µu¼È¤þÓi»ÄÓi°òÂಾ酶¡]ALT¡^¤É°ª¡B¥Nªí¨x²ÓM¨ü·l±¡§Î¡C]
[¤AñQÓi×ô¦b«ØijªvÀø¾¯¶q(4g)¤U¡A¤]´¿¦³µu¼È¤þÓi»ÄÓi°òÂಾ酶¡]ALT¡^¤É°ª¡B¥Nªí¨x²ÓM¨ü·l±¡§Î¡C]
2022.11.19¸Ñ¼öÂíµh¤AñQÓi×ô¹L¶q¶Ë¨x ¥x¬ãµo·s°t¤è¦³®Ä°¨x¬rhealth.ltn.com.tw/article/paper/1552287
SNP-810 Á{§É¼Æ¾Ú´îNAPQI§Î¦¨:Dr. Richard C. Dartªí¥Ü¡A¤AñQÓi×ô¦b«ØijªvÀø¾¯¶q¤U¡A¤]´¿¦³µu¼È¤þÓi»ÄÓi°òÂಾ酶¡]ALT¡^¤É°ª¡B¥Nªí¨x²ÓM¨ü·l±¡§Î¡C
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
Sponsor:Richard Dart, MD, PhD
Collaborator:Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Information provided by (Responsible Party):Richard Dart, MD, PhD, Denver Health and Hospital Authority
---------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/10/20 ¤U¤È 07:42:55²Ä 2627 ½g¦^À³
¦n©_TYNADOTE®(SNP-820)±q¤¤¤î(¼È°±)¦Ó«±ÒÁ{§É¸ÕÅ窺½t¥Ñ? ²ö«D·Qµ¹J&Jªº¸Ñ¬r¾¯ FomepizoleÀ£¤O?
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
clinicaltrials.gov/ct2/show/NCT05517668?term=Fomepizole&draw=2&rank=2
---------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2020/9/14 ¤W¤È 09:46:29²Ä 350 ½g¦^À³
ªYÄ£SNP-820(¹ï¤AñQÓi×ô¸Ñ¬r¾¯)¨Ã«D°ò©ó¥«³õ§Q¼í¦Ò¶q(¥Õ¸Ü´N¬OÁȤ£¤F¿ú)¡A¦Ó¬O±q¤½¦@½Ã¥Íªº¨¤«×«ä¦Ò¡A§Æ±æ¥H¬ãµo·sÃijyºÖ¯f±w¡A¥HºÉ¨ì¤½¥q¤§ªÀ·|³d¥ô¡C
www.vbdata.cn/1518896904
Madrigal¤½¥q¦b¢»´Á临§É时调¾ã¤F¨x纤维¤Æ««×±wªÌªº¤ñ¨Ò¡CMadrigal¤½¥q¦b¢º´Á临§É时©Û¶Òªº±wªÌ§ó¦h处¤_¨x纤维¤ÆF1©MF2´Á¡A¦Ó¦b
[临§É¢»´Á时¡AMadrigal¤½¥q©Û¶Òªº±wªÌ¤j¦h处¤_¨x纤维¤ÆF3´Á¡A¦b这¨Ç««×±wªÌ¤¤¦w¼¢剂§@¥Î´N¬Û对®z¤F«Ü¦h¡C]
[临§É¢»´Á时¡AMadrigal¤½¥q©Û¶Òªº±wªÌ¤j¦h处¤_¨x纤维¤ÆF3´Á¡A¦b这¨Ç««×±wªÌ¤¤¦w¼¢剂§@¥Î´N¬Û对®z¤F«Ü¦h¡C]
当µM¡A还¦³§ó¦y锐ªº问题©|¥¼¸Ñú¨¡GMadrigal¤½¥q§Y¨Ï¬O¦b临§É设计¤W°µ¤Fɬ¤Æ¡A
[¦ý¤´¦³70%¥H¤W±wªÌ¦b¥Dn终点¤W没¦³©ú显§ïµ½¡A药®Ä还¦³«Ü¤jªº´£¤ÉªÅ间¡C]
[¦ý¤´¦³70%¥H¤W±wªÌ¦b¥Dn终点¤W没¦³©ú显§ïµ½¡A药®Ä还¦³«Ü¤jªº´£¤ÉªÅ间¡C]
[¦ý¤´¦³70%¥H¤W±wªÌ¦b¥Dn终点¤W没¦³©ú显§ïµ½¡A药®Ä还¦³«Ü¤jªº´£¤ÉªÅ间¡C]
----------------------------------------------------------------------------------------
µ²½×:调¾ã¤F¨x纤维¤Æ««×±wªÌªº¤ñ¨Ò+ ¥[ªøªvÀø´Á (¤G´ÁªvÀø´Á 36¶g ¡A¤T´ÁªvÀø´Á 52¶g)¡C
¥t¥~¡A¥h¦~¤~¥[¶}ªº¨x纤维¤ÆF4´ÁªvÀø´Á 3¦~!
2020.10.19 ¥ÛªF줧°t°¸ -¥Ó³øÂàÅý±i¼Æ100 ÂàÅý´Á¶¡10/22~11/21
¥ÛªFì -¥Ó³øÂàÅý±i¼Æ 227 ÂàÅý´Á¶¡10/22~11/21
--------------------------------------------------------------------------------
2020.12.21¤½§iSNP-810·sÃÄ»P°ê»ÚÃļtñq·sÃĬãµo¦X§@¨óij¡C
´Á¶¡ªÑ»ù¨«¶Õ?¨Æ¹ê¤]¤£ºÉµM¡A³Ì¦n¥h¹qµo¨¥¤H°Ý°Ý!
__________________________________________
ÁÂÁ¾¾¤j®ø®§. ²{¦b¶¥¬q³oÃþ®ø®§¤ñ¹êÅç½×¤å«¬¤Î¥«³õ¦h¤j»·´º¦h¬ü¦nÃþ°T®§¹ê»Ú. ¦pªG¤º³¡¥DºÞ¦b½æ, ¥i¤£¬O¦n¨Æ.
¨xÅÖºû¤Æ¬O¦hºØ¯f¦]¾ÉPªººC©Ê¨xŦ¯e¯f¡C¨ä¥Dn¯S¼x¬O¨xŦ¤ºÄjº©©Êªº¡B¹L¶qªº²ÓM¥~°ò½èECM(¯S§O¬O½¦ì)¨I¿n¡Cªñ´Á¬ã¨sªí©ú¡A¦pªG¯àµ¹¤©¦³®Äªº¯f¦]ªvÀø¡A©Î¯àª½±µ[§í¨î]ECMªº¦X¦¨©M©Î[«P¶i]ECM°¸Ñ¡A¤w¸g§Î¦¨ªº¨xÅÖºû¤Æ¬Æ¦Ü¬O¥i¥H°fÂ઺!
m.medsci.cn/article/show_article.do?id=1f6fe550173d
¦b进®i©Ê¨xºC©Ê损伤¤¤¡AECMªº¥Í¦¨°¸Ñ[¥¿Å状态]³Q¥´¯}¦Ó¤j¶q¨I积¬O¨x纤维¤Æªº«n¯S©º¡C
...TGF-£]1 ¬O诱导纤维胶ì(¥Dn¬OI«¬©MIII«¬)¡B£\-SMA¡B
¨x损伤´Á间ª÷属³J¥Õ酶组织§í¨î剂(Timp)ªº«ù续产¥Í¥i¥H§í¨î°ò质ª÷属³J¥Õ酶(MMP)ªº¬¡©Ê¡A¨Ï±oª÷属³J¥Õ酶对¦h§Eªº纤维胶ì¥h°£®Ä²v°§C¡A¥´¯}°ò质°¸Ñ¦X¦¨ªº¥¿Å¡A从¦Ó«P进细M¥~°ò质ªº¨I积¡C
---------------------------------------------------------------------------------------------------
¾Ú¦¹2018¦~Gileadªá15»õ¬ü¤¸±ÂÅvTGF£]ÃĪ«
finance.yahoo.com/news/gilead-partners-scholar-rock-fibrotic-225910808.html
...³o¨Ç¶µ¥Ø°w¹ï¤@ºØºÙ¬°Âà¤Æ¥Íªø¦]¤l £] ©Î TGF£] ªº²ÓM«H¸¹³J¥Õ¡A¥Î©óªvÀøÅÖºû¤Æ¯e¯f¡C
«D±`¥i±¤ªº¸ÕÅç¶i«×½wºC
ªÑ»ùµL¤O¸ò¤W°ê»Ú¸}¨B
¥h¦~¤w§ï¿ï¸³ºÊ¨Æ
¦pªG¬O¤µ¦~§ï¿ï´N¥þ¤O¤ä«ùR¤j¶i¸³¨Æ·|
¬ÝR¤j¦p¦¹¥Î¤ß¡B¿n·¥ªº§ä´M»PªYÄ£¬ÛÃö¸ê®Æ
¯u¬OÅý¤H·P°Ê
...¼Æ¾ÚÅã¥Ü¡ACYP2E1 ¨Ì¿à©Ê ROS ¼W¥[¤F¨x²ÓM©M HSC ¦@°ö¾iª«¤¤ªº½¦ì³J¥Õ¦X¦¨¡A
[ªí©ú CYP2E1 »P¨xÅÖºû¤Æ±K¤Á¬ÛÃö [ 54 ]
[ªí©ú CYP2E1 »P¨xÅÖºû¤Æ±K¤Á¬ÛÃö [ 54 ]
-------------------------------------------------------------------------------------------------
¨xÅÖºû¤Æ: Col1a1:I«¬½¦ì³J¥Õ / Col3a1:III«¬½¦ì³J¥Õ
1.ªYÄ£:£\-SMA-SMA¡BCol1a1¡BCol3a1©MTimp-1§¡ÅãµÛ°§C¡C
2.Intercept(OCA) www.ncbi.nlm.nih.gov/pmc/articles/PMC5025787/
£\-SMA¡BCol1a1¡B Timp-1--->ÅãµÛ°§C
3.Madrigal(Resmetirom) bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.15427
...ResmetiromªvÀø«á¡A¨xŦcol1a1¡B£\-SMA©Mgal-3§t¶q°§C¡]¹Ï4¡^¡C»P¸üÅéªvÀøªºDIO-NASH¤p¹«¬Û¤ñ¡A
[£\-SMAªº®t²§¦bÂk¤@¤Æ¬°¨xŦ«¶q«á¤´¦³²Îp¾Ç·N¸q¡A¦ýcol1a1ªº®t²§«h¨S¦³¡]¥¼Åã¥Ü¡^]-¦pªG®É¶¡©ÔªøÀ³¸Ó¦³²Îp¾Ç·N¸q
[£\-SMAªº®t²§¦bÂk¤@¤Æ¬°¨xŦ«¶q«á¤´¦³²Îp¾Ç·N¸q¡A¦ýcol1a1ªº®t²§«h¨S¦³¡]¥¼Åã¥Ü¡^]-¦pªG®É¶¡©ÔªøÀ³¸Ó¦³²Îp¾Ç·N¸q
--------------------------------------------------------------------------------------------------
·|û¡GRock00910149258 µoªí®É¶¡:2022/10/19 ¤U¤È 05:04:37²Ä 2619 ½g¦^À³
1.¨Æ¹êµo¥Í¤é:111/10/19...¤@¡BSNP-630ªvÀøªº¤p¹«ªº¨xµoª¢¡B¨x¯×ªÕÅÜ©Ê©MÅÖºû¤Æ±o¨ìÅãµÛ§ïµ½¡A¨äALT¤ô¥¡B
ÅÖºû¤Æ¬ÛÃö¥Íª«¼Ð°O¡]§Yalpha-SMA¡BCol1a1¡BCol3a1©MTimp-1¡^§¡ÅãµÛ°§C¡C
-------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤W¤È 08:30:15²Ä 2172 ½g¦^À³
F4°ò¥»ºâ¬O¥Ø«eÃĪ«¬ãµoªº¸T°Ï¡A¯e¯f¶i®i¨ì¨xµw¤Æ¤§«á¦A°fÂà¬O«D±`§xÃøªº¡A¦pªG¯à°µ¥XÀø®Ä¡A¯uªº´N¤jº¡³e¤F¡C
©Ò¥HSNP-610´Á¤¤¤ÀªR:F4ªº²Õ¡AªvÀø«e«á¦³[ÅãµÛ®t²§]
ì¦]:Á{§É¤G´Áªº[ÅÖºû¤Æ]§ïµ½¼Æ¾Ú¤£¨Î(«á¨Óªº¤T´ÁÁ{§É¦³©ÔªøªvÀø®É¶¡)
bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.15427
4.°Q½×
...¥Ø«e©|¤£²M·¡³o¬O¥Ñ©ó¯Ê¥FÀø®ÄÁÙ¬O 36 ¶gªºªvÀø«ùÄò®É¶¡¤Óµu¦ÓµLªk¤Þ°_¥iÆ[¹î¨ìªº¨xÅÖºû¤Æ§ïµ½...¨Ã¥B¨Ï¥Î·ç¬ü´Àù¥¼Æ[¹î¨ìÅÖºû¤Æµû¤À¦³ÅãµÛ§ïµ½¡C
...³ÌªñÆ[¹î¨ìÅÖºû¤Æ§ïµ½ªºÃĪ«¬O¶ø¨©Áx»Ä(OCA)¡G¦b³Ìªñ³ø§iªº¤@¶µ III ´Á¸ÕÅ窺¤¤´Á¤ÀªR¤¤¡A¦b±µ¨üªvÀøªºÓÅ餤Æ[¹î¨ìÅÖºû¤Æ¦Ü¤Ö§ïµ½¤F¤@Ó¶¥¬q¨Ï¥Î OCA¡A»P¦w¼¢¾¯¬Û¤ñ¡A18 Ó¤ë«á¤j¬ù¬O resmetirom II ´Á¸ÕÅ窺¨â¿
...[©ÎªÌ¦P¼Ë¡A§óªø®É¶¡ªºresmetiromªvÀø¥i¯à¾ÉP±wªÌÅÖºû¤Æ§ïµ½¡C]
[©ÎªÌ¦P¼Ë¡A§óªø®É¶¡ªºresmetiromªvÀø¥i¯à¾ÉP±wªÌÅÖºû¤Æ§ïµ½¡C]
-------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/12/20 ¤W¤È 08:39:24²Ä 2739 ½g¦^À³
Madrigal¤½¥qªº³Ð©l¤H¤Ò°ü±qRoche§â³oÓ²£«~®³¥X¨Óªº®ÉÔ¡A´N¨Sp¹ºµÛ§â²£«~°µ¨ì¤W¥«¾P°â¡C§{¶¡¶Ç»D»¡¥»¨Óp¹ºµÛ¤G´Á¼Æ¾Ú¥X¨Ó¤§«á´N¥X¤â¡A¦ý¬O¶û¦UÓ¶R®a³øªº»ù®æ¤Ó§C....
cyp2e1§í¨î¤]¦³µÛ¬Û¦Pªº§@¥Î¾÷¨î¡A¦Ü©ó¬O¹v¦V¤W´å©Î¤U´åªº®ÄªG¤j¡A´Nµ¥¸ÕÅçÅçÃÒ!
½u²ÉÅé¥\¯à»Ùê¦b NASH ¶i®i¤¤°_µÛ®Ö¤ß§@¥Î!
rupress.org/jem/article/220/4/e20221738/213867/The-genetic-background-shapes-the-
susceptibility
-----------------------------------------------------------------------------------------------
¤d¨¥¸U»y¤£¦p¤@±i¹Ï¨ÓªºÂ²³æ©úÁA!
Graphical Abstract---¦³7°¦ mice¡APWK/PhJ ¬O¥kÃäÂŦâ¡C
½u²ÉÅé¥\¯à»Ùê¦b NASH ¶i®i¤¤°_µÛ®Ö¤ß§@¥Î!
----------------------------------------------------------------------------------------------
Madrigal¤½¥qªºResmetirom:
www.madrigalpharma.com/our-programs/resmetirom/
THR-£] §@¥Î¬O¥¿±`¨x¥\¯àªºÃöÁä¡A¥]¬A½Õ¸`½u²ÉÅ鬡©Ê¡]¨Ò¦p¨x¯×ªÕ¤À¸Ñ¡^©M±±¨î¥¿±`¡B°·±dªº½u²ÉÅé¤ô¥¡C
1. 2023.2.14--NASH©ö·P©Êªº¿ò¶Ç®t²§(¸ê§UªÌ:Janssen Pharmaceuticals¼b¥Í¶°¹Î)
rupress.org/jem/article/220/4/e20221738/213867/The-genetic-background-shapes-the-
susceptibility
...§ÚÌ´ú¸Õ¤F¤CºØ¤p¹««~«Y¹ï NASH ªº©ö·P©Ê...
[ªí©ú½u²ÉÅé¥\¯à»Ùê¦b NASH ¶i®i¤¤°_µÛ®Ö¤ß§@¥Î¡C]
[ªí©ú½u²ÉÅé¥\¯à»Ùê¦b NASH ¶i®i¤¤°_µÛ®Ö¤ß§@¥Î¡C]«nªº¡APWK/PhJ ¤p¹«ªº NASH °ò¦]ªí¹FÃлP¤HÃþNASH ¯S¼xªº«
Å|«×³Ì°ª¡C
2.2017.5.1--CYP2E1 ½u²ÉÅé©w¦ìªº¬r²z¾Ç·N¸q
www.ncbi.nlm.nih.gov/pmc/articles/PMC5627779/
¦ì©ó½u²ÉÅ餺½¤¤Wªº CYP2E1 ¥i³q¹L©³ª«®ñ¤Æ²£¥Í¤ÏÀ³©Ê¥NÁª«©M/©Î¦b¨ä¶Ê¤Æ´`Àô¸Ñ°¸Áp®É²£¥Í ROS¡A±q¦Ó¯}Ãa½u²ÉÅé
DNA¡B³J¥Õ½è©M¯×½è¡C¤Ï¹L¨Ó¡A³oºØ·l¶Ë·|¾ÉP½u²ÉÅé¹q¤l¶Ç»¼Ã줤 ROS ªº²£¥Í¼W¥[¡A±q¦Ó¶i¤@¨B·l¶Ë½u²ÉÅé¡A³Ì²×¾É
P²ÓM¤¤ªº½u²ÉÅé¥\¯à»Ùê¡C
----------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/10 ¤W¤È 08:50:01²Ä 2876 ½g¦^À³
ªYÄ£¦b§í¨îCYP2E1¬O±j¶µ¡AÂX±i©Ê¤ß¦Ù¯fDCM¤]¦n¦nµo´§§a!(¾Ú§ÚÌ©Òª¾¡A¨ì¥Ø«e¬°¤îÁÙ¨S¦³¬ÛÃö¬ã¨sªº³ø¾É)
2022.11.1 ¼b¥Í¤½¥q¥H166»õ¬ü¤¸¦¬ÁÊAbiomed ¥HÂX¤j¨ä¤ß¦åºÞ·~°È(°w¹ï«æ©Ê¤ßŦ°IºÜ±wªÌ´£¨Ñ¤ßŦ´_µd´`Àô¤ä«ù¤Î«ùÄò·ÓÅ@¤§ÂåÀø¾¹§÷ªº¬ã¨s¡B¶}µo¤Î¾P°â)
.... CYP2E1 ¬O²ÓM©M½u²ÉÅé ROS/RNS ªº¥Dn¨Ó·½
1. ¥xÆW¦ÑÁó¤£Ä@¦¨¬°¥t¤@®a¤j¤½¥q¨Æ·~¸sÁ`¸g²z;
2. ²{¦b¥«È§C, µLªkÀò¹ï¤è¸³¨Æ·|¦P·N°ª»ù;
3. ÁÙ¦³6¨t¦C¦p¦óp»ù? n8¨t¦Cªº¥¼¥²·R6¨t¦C.
§Úı±o²{¦b¤Wµ¦, ÁÙ¬O½Í±ÂÅv810. µM«á±ÂÅv§¹IPO.
¦U¦ì$25¶Rªº¨S°ÝÃD,«ç¼Ë³£¤jÁÈ. §Ú¤µ¦~¶i³õÀ£¤O¸û¤j. ¨ä¹ê쥻´N¹wp1¦~«á§¹¦¨±ÂÅv. ªÑ²¼«ù¦³2¦~. ¤£¹L³Ì¾á¤ßªº¬O¨ä¶¡¤j¼t¦¨¥\±À¥XÃþ¦ü²£«~. ¥H«e§Ú§ëªº¤@®a¥Í§Þ´N¹J¨ì³oºØª¬ªp. ÁÙ¬Oı±o¤j®a¦hª`·N810¼Ï¶s¤Î±ÂÅv¶i«×.
¡X¡X¡X¡X¡X¡X¡X¡X¡X-
³oÂI§Ú¤]»{¦P
¥Ø«eªº®ÉªÅI´º¤S¤£¤@¼Ë¤F
810¤w¹Gªñ¦¨¥\¶¥¬q
§ó¬O³o¨â¤j¼t¦³»Ý¨DªºÃÄ
³B¤è¤Î«D³B¤èÃÄ¡A¨C¦~¶W¹L¦Ê»õ¬ü¤¸¡C
ªYÄ£ªº»ùȤw§ó°ª
·Qn§C»ù¨ÖÁÊ¡A§O·Q¤F¡I
°£«D¶}¥XÅý¤HµLªk©Úµ´ªº»ù½X
www.nature.com/articles/s41467-022-31812-4
...³Ìªñªº¤@½g½×¤å³ø¾É¤F¤@Ó¤£¦PªºÆ[¹îµ²ªG¡A§YHsd17b13°ò¦]ºV°£¤p¹«¦b´XºØ¯×ªÕ¨x»¤¾Éªº¶¼¹±ø¥ó¤U¡A¦b¨x¯×ªÕÅÜ
©Ê¡B¨x·l¶Ë¡BÅÖºû¤Æ©Mª¢¯g¤è±»P WT ¤p¹«¨S¦³®t²§!
---------------------------------------------------------------------------------------------
¿Õ¨©º¸¥Í²zÂå¾Ç¼ú±o¥DBruce Beutlerªº½×¤å
¤£·|¼vÅTJ&J¨M©w²×¤îArrowheadªºNASH±ÂÅv¬ù?
Ó¤H»{¬°ì¥ýñq¦X§@¨óij¨ì´Á«áªº¨º®a°ê»Ú¤jÃļt¿ð¿ð¨S¦³¤U¤å¡A«áÄò¦n¹³¤]¨S¦³¨ä¥LÃļtñ¦X§@¨óij¡A©Î³\¥i¯à¦³µo²{¬Y¨Ç°ÝÃD¡K.
-------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2021/12/2 ¤W¤È 08:20:48²Ä 1497 ½g¦^À³
....1. ¤G®a¦P¦b2018¦~»PArrowheadñq¦X§@¨óij
2021.11.30´´ËÃļt»P¸¯Äõ¯À¥v§JÃļt¡^¤À§O¦b³Ìªñ¤@¶g¤º«Å¥¬§ë¤J¥Ñ¬ü°êÃļtArrowhead Pharmaceuticals «D°sºë©Ê¯×ªÕ©Ê¨xª¢»â°ìRNA¤zÂZªvÀø¬ãµo¡A¨ä¹ê¨â®aÃļt¬Ò¦¤w©ó2018¦~´N»PArrowheadñq¦X§@¨óij¡C
geneonline.news/nash-janssen-gsk-rnai/
....
------------------------------------------------------------------------------------------
J&J»PGSK³o¤G®a¬O¦b2018¦~¸òArrowheadñq[¦X§@¨óij]¡A3¦~«á¡AJ&J»PGSK¦b2021¦~¸òArrowheadñ[±ÂÅv¬ù]¡C
µu´Á¤º¨S®ø®§ªÑ»ù¤£·|º¦´N¬O¸gÀç°ÝÃD¤F¶Ü¡K¤@ª½®³§O®aÃļtªº±ÂÅv®Éµ{¨Ó¤ñ¸û¥u·|¥¢±æ¦Ó¤w